<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="166001"><TitleDisplay>Phase IIb Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis</TitleDisplay><TitleOfficial>A Phase IIb, Randomized, Multicenter, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02015520</Identifier><Identifier type="Secondary Organisational">2013-003780-65</Identifier><Identifier type="Organisational Study">IM133-066</Identifier><Identifier type="Other">JapicCTI-142497</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="781" role="Therapeutic effect marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>clazakizumab</Name><Drug id="59143">clazakizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59143">clazakizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1123559">Vitaeris Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59143" type="Drug"><TargetEntity id="468410" type="siDrug">Clazakizumab</TargetEntity></SourceEntity><SourceEntity id="1123559" type="Company"><TargetEntity id="5050921010" type="organizationId">Vitaeris Inc</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2b Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>58</NumberOfSites><CompaniesSponsor><Company id="1123559">Vitaeris Inc</Company><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="471">IL-6 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="85">Protein recombinant</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>143</PatientCountEnrollment><DateStart>2012-06-30T00:00:00Z</DateStart><DateEnd type="actual">2015-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T00:55:17Z</DateChangeLast><DateAdded>2014-01-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bristol-Myers Squibb</Affiliation><Name>Bristol-Myers Squibb</Name></Contact><Contact type="Scientific contact"><Affiliation>BRISTOL MYERS SQUIBB DE MEXICO, S DE RL DE CV</Affiliation><Email>teresa.linaresorrala@bms.com</Email><Name>Teresa Linares Orrala</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association [ARA] [1987] or American College of Rheumatology/European League Against Rheumatism [ACR/EULAR] [2010]) at least 16 weeks prior to screening&lt;/li&gt;&lt;li&gt;ACR global functional status class of 1 to 3&lt;/li&gt;&lt;li&gt;Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors&lt;/li&gt;&lt;li&gt;All patients must have been receiving treatment with a minimum dose of 15 mg per week of methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with hydroxychloroquine or chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening&lt;/li&gt;&lt;li&gt;Minimum of six swollen and six tender joints on a 66/68 joint count at screening and at baseline (day 1)&lt;/li&gt;&lt;li&gt;Elevated high-sensitivity (hs) CRP and/or ESR&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active serious infection&lt;/li&gt;&lt;li&gt;History of or active tuberculosis (TB)&lt;/li&gt;&lt;li&gt;Elevated liver function tests (LFTs)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Disease activity score in 28 joints- C-reactive protein (DAS28-CRP) change</Description><Timeframe>Baseline (day 1) and week 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>American College of Rheumatology (ACR) 20/50/70 responses</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>Boolean Remission</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>Clinical Disease Activity Index (CDAI)</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>DAS28- Erythrocyte Sedimentation Rate (ESR) &lt; 2.6</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>DAS28-CRP &lt; 2.6</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>Health Assessment Questionnaire Disability Index (HAQ-DI) change</Description><Timeframe>Baseline (day 1) and week 12</Timeframe></Measure><Measure><Description>Safety based on adverse events (AEs), vital signs, physical examinations, safety lab values and immunogenicity during the double-blind period</Description><Timeframe>Up to week 12</Timeframe></Measure><Measure><Description>Simplified Disease Activity Index (SDAI)</Description><Timeframe>At week 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were presented in May 2015. &lt;ulink linkType="Drug" linkID="59143"&gt;Clazakizumab&lt;/ulink&gt; was well tolerated and there were no differences in terms of adverse events or laboratory safety data from placebo [&lt;ulink linkType="Reference" linkID="1656748"&gt;1656748&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to identify an appropriate dose of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; (BMS-945429) and to evaluate the efficacy and safety of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; in patients with moderate to severe active rheumatoid arthritis who were anti-TNF inadequate responders [&lt;ulink linkType="Reference" linkID="1656748"&gt;1656748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The primary objectives of the study was to compare the efficacy of clazakizumab versus placebo on a background of methotrexate as assessed by change from baseline in DAS28-CRP at 12 weeks.&lt;/para&gt;&lt;para&gt;The secondary objectives of the study were to:&lt;br/&gt;Assess the efficacy of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; on a background of methotrexate in reducing signs and symptoms of rheumatoid arthritis by measures such as ACR rates, remission rates and Disease activity score- C-reactive protein (DAS28-CRP) &amp;lt; 2.6, over 12 weeks of treatment.&lt;br/&gt;Assess the efficacy of clazakizumab on a background of methotrexate in improving physical function as determined by change from baseline in HAQ-DI at 12 weeks of treatment.&lt;br/&gt;Assess the safety of clazakizumab on a background of methotrexate by assessment of Adverse Events (AEs) and laboratory parameters.&lt;br/&gt;Characterize the pharmacokinetics, immunogenicity, pharmacodynamics and biomarker responses of different &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; doses on a background of methotrexate.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were presented in May 2015. Primary endpoint was met. The dosing groups 25 and 5 mg were statistically significantly better than placebo at p &amp;lt; 0.001 [&lt;ulink linkType="Reference" linkID="1656748"&gt;1656748&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of five treatment groups:&lt;br/&gt;Group 1(double-blind): patients would receive dose A sc injection of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; for 12 weeks and background methotrexate.&lt;br/&gt;Group 2 (double-blind): patients would receive dose B sc injection of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; for 12 weeks and background methotrexate.&lt;br/&gt;Group 3 (double-blind): patients would receive dose C sc injection of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; for 12 weeks and background methotrexate.&lt;br/&gt;Group 4 (double-blind): patients would receive placebo   matching with &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; for 12 weeks and background methotrexate.&lt;br/&gt;Group 5 (open-label):  any patients who complete the double-blind study would receive dose A sc injection of &lt;ulink linkType="Drug" linkID="59143"&gt;clazakizumab&lt;/ulink&gt; and background methotrexate for 96 weeks. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received clazakizumab versus placebo  [&lt;ulink linkType="Reference" linkID="1656748"&gt;1656748&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="377592">clazakizumab</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Subcutaneous</Route></Treatment><Treatment><Dose>25 milligram</Dose><Route>Subcutaneous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Name>Local Institution</Name><Address1>Buenos Aires</Address1><Address3>1121</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Buenos Aires</Address1><Address3>1426</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Cordoba</Address1><Address3>5000</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Quilmes</Address1><Address2>Buenos Aires</Address2><Address3>1878</Address3><CountrySubDivision>Buenos Aires</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Tucuman</Address1><Address3>4000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Cividino Medicine Professional Corporation</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><Address3>L8N 2B6</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Credit Valley Rheumatology</Name><Address1>Mississauga</Address1><Address2>Ontario</Address2><Address3>L5M 2V8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Dr. Latha Naik Medical Professional Corporation</Name><Address1>Saskatoon</Address1><Address2>Saskatchewan</Address2><Address3>S7K 3H3</Address3><CountrySubDivision>Saskatchewan</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Local Institution</Name><Address1>Bordeaux Cedex</Address1><Address3>33076</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Paris Cedex 14</Address1><Address3>75679</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Poitiers</Address1><Address3>86021</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Name>Local Institution</Name><Address1>Budapest</Address1><Address3>1023</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Debrecen</Address1><Address3>4012</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Veszprem</Address1><Address3>8200</Address3><Contacts></Contacts></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>GCT-SU</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>EU Study Start-Up Unit</Name></Contact></Contacts></Site><Site><Name>Local Institution</Name><Address1>Catanzaro</Address1><Address3>88100</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Firenze</Address1><Address3>50139</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Napoli</Address1><Address3>80131</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Pisa</Address1><Address3>56126</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Japan"><Sites><Site><Name>Local Institution</Name><Address1>Chiba-shi</Address1><Address2>Chiba</Address2><Address3>2608712</Address3><CountrySubDivision>Chiba</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Kato-shi</Address1><Address2>Hyogo</Address2><Address3>6731462</Address3><CountrySubDivision>Hyogo</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Kitakyushu-shi</Address1><Address2>Fukuoka</Address2><Address3>8078555</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Nagano-shi</Address1><Address2>Nagano</Address2><Address3>3808582</Address3><CountrySubDivision>Nagano</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Nishimuro-gun</Address1><Address2>Wakayama</Address2><Address3>6492211</Address3><CountrySubDivision>Wakayama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Sasebo-shi</Address1><Address2>Nagasaki</Address2><Address3>8571195</Address3><CountrySubDivision>Nagasaki</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Shinjuku-Ku</Address1><Address2>Tokyo</Address2><Address3>1608582</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Toshima-ku</Address1><Address2>Tokyo</Address2><Address3>1708476</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Mexico"><Sites><Site><Name>Local Institution</Name><Address1>Guadalajara</Address1><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Leon</Address1><Address2>Guanajuato</Address2><Address3>37000</Address3><CountrySubDivision>Guanajuato</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Merida</Address1><Address2>Yucatan</Address2><Address3>97000</Address3><CountrySubDivision>Yucatan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Merida</Address1><Address2>Yucatan</Address2><Address3>97070</Address3><CountrySubDivision>Yucatan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>San Luis Potosi</Address1><Address3>78200</Address3><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Tijuana</Address1><Address2>Baja California</Address2><Address3>22010</Address3><CountrySubDivision>Baja California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Rheumatology Clinic and Obesity Research, SC</Name><Address1>Guadalajara</Address1><Address2>Jalisco</Address2><CountrySubDivision>Jalisco</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Albuquerque Center For Rheumatology</Name><Address1>Albuquerque</Address1><Address2>New Mexico</Address2><Address3>87102</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Albuquerque Clinical Trials</Name><Address1>Albuquerque</Address1><Address2>New Mexico</Address2><Address3>87102</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arthritis &amp; Rheumatology Center Of Oklahoma Pllc</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73103</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Center For Inflammatory Disease</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cincinnati Rheumatic Disease Study Group</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45219</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Pharmacology Study Group</Name><Address1>Worcester</Address1><Address2>Massachusetts</Address2><Address3>01605</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Desert Medical Advances</Name><Address1>Palm Desert</Address1><Address2>California</Address2><Address3>92260</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Health Research Of Oklahoma</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73103</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Healthcare Research Consultants</Name><Address1>Tulsa</Address1><Address2>Oklahoma</Address2><Address3>74135</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Joint And Muscle Medical Care And Research Institute (Jmmcri)</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3>28204</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Low Country Rheumatology</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3>29406</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mercy Clinic Hot Springs Communities</Name><Address1>Hot Springs</Address1><Address2>Arkansas</Address2><Address3>71913</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Paramount Medical Research &amp; Consulting, Llc</Name><Address1>Middleburg Heights</Address1><Address2>Ohio</Address2><Address3>44130</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Physician Research Collaboration, Llc</Name><Address1>Lincoln</Address1><Address2>Nebraska</Address2><Address3>68516</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Physicians East, Pa</Name><Address1>Greenville</Address1><Address2>North Carolina</Address2><Address3>27834</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Rheumatology Associates Of North Alabama, P.C.</Name><Address1>Huntsville</Address1><Address2>Alabama</Address2><Address3>35801</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Rheumatology Consultants Pllc</Name><Address1>Knoxville</Address1><Address2>Tennessee</Address2><Address3>37909</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sarasota Arthritis Research Center</Name><Address1>Sarasota</Address1><Address2>Florida</Address2><Address3>34239</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Seattle Rheumatology Associates</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98122</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Paul Rheumatology, P.A.</Name><Address1>Eagan</Address1><Address2>Minnesota</Address2><Address3>55121</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Valerius Med Group &amp; Res Ctr Of Greater Long Beach, Inc.</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90806</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="South Africa"><Sites><Site><Name>Local Institution</Name><Address1>Cape Town</Address1><Address2>Western CAPE</Address2><Address3>7500</Address3><CountrySubDivision>Western CAPE</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Local Institution</Name><Address1>Stellenbosch</Address1><Address2>Western Cape</Address2><Address3>7600</Address3><CountrySubDivision>Western Cape</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="499">Moderate Rheumatoid Arthritis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="500">Severe Rheumatoid Arthritis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="502">Active Rheumatoid Arthritis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="513">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02015520</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2013-003780-65</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-142497</Identifier></Identifiers></Registry><Registry><Name id="1033">Federal Commission for Protection against Health Risks (COFEPRIS) Clinical Trials Registry
</Name><Identifiers><Identifier></Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Rheumatoid arthritis" id="3900"><Endpoint>DAS-28 (Disease Activity Score) Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4000">Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Rheumatoid arthritis" id="3883"><Endpoint>American College of Rheumatology (ACR) 20 Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3884"><Endpoint>American College of Rheumatology (ACR) 50 Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3885"><Endpoint>American College of Rheumatology (ACR) 70 Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3900"><Endpoint>DAS-28 (Disease Activity Score) Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3912"><Endpoint>Composite Indices or Pooled indices for evaluation of Disease Activity</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="3913">Simplified Disease Activity Index (SDAI)</SubEndpoint><SubEndpoint disease="Rheumatoid arthritis" id="3914">Clinical Disease Activity Index (CDAI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3924"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="3934">Health Assessment Questionnaire-Disability Index (HAQ-DI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4000">Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4104"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4112"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4144"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4155"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4100">Physical assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="45616"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4017">Erythrocyte sedimentation rate (ESR)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rheumatoid arthritis" id="1897"><Criterion>Moderate Rheumatoid Arthritis</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1898"><Criterion>Severe Rheumatoid Arthritis</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1900"><Criterion>Active Rheumatoid Arthritis</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1906">Active disease with swollen joint count</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1907">Active disease with tender joint count</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1914"><Criterion>ACR Functional Status Classification for Rheumatoid Arthritis</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1915">ACR functional class I</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1916">ACR functional class II</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1917">ACR functional class III</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1931"><Criterion>Subjects on Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1932">Subjects on methotrexate (MTX)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1940"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1969"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1938">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="33268"><Criterion>Subjects with Abnormal Laboratory Parameters</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1908">Increased C-reactive protein (CRP) level</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2922"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2923">Subjects co-morbid with tuberculosis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>33.06 Months</EnrollmentPeriod><EnrollmentRate>4.33 Patients/Month</EnrollmentRate><DateFirstReceived>2013-12-06T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-02-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-05-14T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2015-08-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>